Green Hydrogen As A Key To Carbon Free Economy


As more countries are interested in adopting decarbonization strategies, hydrogen has a critical role. Applying this feat will be particularly difficult in sectors where direct electrification is challenging, for example, in harder-to-abate sectors, such as steel, chemicals, long-haul transport, shipping, and aviation. The pre-requisite for this is for hydrogen production to involve lower carbon and, ultimately, a green mode of production. This green hydrogen is produced by water electrolysis using renewable forms of electricity.

In addition to system regulations and market design, production costs are considered a significant barrier to green hydrogen uptake. Prices of renewable power sources are falling, but green hydrogen is still double as expensive as the blue hydrogen produced from fossil fuels, including carbon capture and storage, making it unsustainable. Further cost reductions are needed to broaden companies' use of green hydrogen.

The most significant production cost component for green hydrogen on-site generation is the renewable electricity cost that powers the electrolyzer unit. This cost challenge makes green hydrogen production more expensive than blue hydrogen, irrespective of the electrolyzer's cost. Therefore, a lower price of electricity is necessary to produce competitive green hydrogen in the current scenario. Locations with optimal renewable resources can effectively produce green hydrogen to achieve a carbon-free advantageous edge.

Lowering the cost of electricity supply is not enough to achieve a competitive green hydrogen production. Along with this, reductions in the price of electrolysis facilities are also needed. This is considered the second largest cost component in green hydrogen production; it identifies critical strategies that reduce investment costs for electrolysis plants. These strategies are multifaceted and can range from the electrolyzer stack's fundamental design to broadening the system-wide elements.

Production of Green Hydrogen

Hydrogen production using water electrolyzers can be equipped with an anion exchange membrane (AEM), a water feed, and several cheap components like platinum metal-free catalysts and stainless-steel bipolar plates (BPP). The AEM electrolyzer’s optimum performance must have a compact design, stability, H2 purity, and high current densities of PEM systems. The current technology in AEM water electrolysis is defined by sporadic reports, mostly dealing with catalyst or membrane development. This technology’s growth needs a roadmap for the systematic development and commercialization of AEM systems and their components.

The development of catalysts, membranes, and ionomers for AEM electrolysis has been sporadic, focusing on integrating the various MEAs and cell testing components. As a result, the best performance data shown in AEM cells has been obtained with commercially available materials. Hence, developing these critical components of this technology is essential for the systematic development and commercialization of AEM systems and components.

Once the challenges of materials development are covered, AEM water electrolysis can drive hydrogen as an energy source in the future, especially in developing countries.

Efficiency is only indirectly indispensable; what bothers is the cost. The electrolysis process’s overall cost comprises the electrolyzer system’s fee, including its maintenance and replacement of damaged membranes, the cost of the electricity, and additional costs for drying, cleaning, gas compression, and transport.

For more information, please visit @ https://www.iebrain.com/green-hydrogen-as-a-key-to-carbon-free-economy/

About Ingenious e-Brain Solutions: -

Ingenious e-Brain Solutions provides high-quality, customized, and cost-effective Technology Intelligence, Business Intelligence, and Intellectual Property Intelligence solutions to industry leaders, and innovative companies across the globe. Innovation, knowledge, and transparency form the basis of our company’s mission and vision. Along with cost benefits, we provide highest quality results ensuring fool-proof confidentiality and security. We are an ISO certified company with offices in India and USA.

Ingenious e-Brain Solutions has a strong team of analysts, and subject matter experts with domain proficiency which is devoted to help clients grow. Our highly qualified professionals offer tailored, value-added and cost-effective services to our clients. We believe in building long term relationships with our clients who include national and international corporations, Fortune 500 companies, world’s leading research institutes and universities as well as independent inventors.

Get in Touch: -
India Office
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, India
+91 124 429 4218

Email: -
queries@iebrain.com

Comments

Post a Comment

Popular posts from this blog

Hybrid Meat Analogues – A Middle Ground between Plant-based & Traditional Meat

Image
I n the context of semi-vegetarian choices, hybrid meat analogues are emerging as an alternative to traditional meat products. These are produced using blends of plant and animal ingredients in varying proportions to provide a meaty taste and texture, with the added nutritional benefits from plants. Compared to plant-based alternatives, hybrid analogues such as burgers, sausages, meatballs, and mince have the potential to reduce GHG emissions by 32% if 50% of meat is replaced by plant proteins. The development of hybrid meat analogues begets opportunities and challenges due to the alterations in technical & sensory properties (texture, appearance, taste, etc.) of the meat matrices caused by plant portion. Technical challenges Major technical challenge faced while blending plant-based proteins with meat proteins is the formation of elastic gels through the enclosure of water and fat particles in the protein network upon heating due to the high emulsifying capacity of myofibrilla...
Read more

IEBS Broadening its Horizons Digitally by Allying with Scientist.com as a Registered Supplier

Image
It is a moment of pride for Ingenious e-Brain Solutions (IEBS) that it has become an affiliated supplier of Scientist.com¬—a renowned digital healthcare research platform. Artificial Intelligence (AI) and digitalization are transcending all technologies and have revolutionized how industries operate. Therefore, IEBS has attempted to grow its digital presence by registering with Scientist.com. As the latter is solely a healthcare domain platform, we offer one element from our extensive list of business consulting solutions at Scientist.com. Here, we deliver healthcare-related latest technological & real-time business insights, emphasize potential opportunities for business propulsion, and provide innovative & strategic enterprise solutions on this platform, particularly for pharmaceuticals, biotechnology, medical technology companies, and clinical research organizations. Scientist.com is an inclusive research platform—with a global network exceeding 4,000 suppliers—encouragi...
Read more

Envisioning the Dual Repercussions of FDA’s Accelerated Approval Pathway

Image
Clinical trials are comprehensive research studies conducted to ensure that recently developed medical interventions, including novel drugs, surgical & other devices, and treatments/ therapies, are safe and effective for human use before commercialization. These trials provide evidence for regulatory bodies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, UK’s Medicines and Healthcare Products Regulatory Agency, and China’s National Medical Products Administration (NMPA) to ensure that a specific medical intervention is safe for the public use, begets limited adverse effects, and meets quality standards. However, it takes 10 to 15 years or even more to complete all three clinical trial phases before reaching the licensing stage. Thus, FDA introduced accelerated or expedite approvals to pace up the approval of drugs that treat severe conditions and address unmet medical needs. Before proceeding with the pros and cons of the FDA’s expe...
Read more